Integral Dental is making waves in the dental industry with the launch of OraclePI, the first early diagnostic test specifically designed for peri-implant disease. Announced on October 30, the innovative product provides a comprehensive diagnosis and personalized care recommendations based on individual patient data.
Dental implants are a crucial solution for those with missing teeth, boasting high success rates. However, the greatest risk to these implants is infection of the surrounding tissue, known as peri-implantitis. OraclePI addressed this challenge by offering clinicians insights into the complete bacterial composition at the implant site, diagnosing infection status, and recommending the most effective antibiotics and treatments.
“This has the potential to improve patient outcomes and drive profitability for dental practices,” stated Rachel Raymond, MBA, Chief Executive Officer of Integral Dental. “As the demand for implants grows, we’re excited to offer an option for personalized management,” she highlighted.
By leveraging advanced genomic sequencing and artificial intelligence, OraclePI provided dentists with actionable insights that enhance patient care.
“We’ve worked hard to make sure our processes fit seamlessly into the daily workflow of the dental office,” says Matt Getz, MBA, Chief Operating Officer of Integral Dental. “Our $110 per test cost to dentists is part of the innovation we’re bringing to the table,” he added.
Early intervention in peri-implant disease is typically more effective and less invasive compared with treatments conducted at later stages of infection. Incorporating diagnostic testing into routine implant management may allow clinicians to identify issues early, ensuring better patient health.
“The specific antibiotic recommendations give us the opportunity to practice true personalized medicine,” underscored Peter Joseph, DMD, a clinical advisor to Integral Dental. “I plan to integrate this tool into my practice and ask all my referring doctors to do the same. The better the information, the better we can help patients,” he suggested.
Integral Dental’s ambitions extend beyond dental health; the company aims to tackle systemic diseases linked to oral pathogens, such as cardiovascular disease, preterm birth, rheumatoid arthritis, and colorectal cancer. Early and effective diagnosis and treatment of oral pathogens can significantly lower health care costs and enhance patient outcomes. Integral Dental is actively exploring new applications for OraclePI, bridging the gap between oral health and overall medical care.
OraclePI is now available for purchase in ten-kit packs for a limited time. More information is available at the company’s website, IntegralDental.bio.
Founded by Rachel Raymond and Matt Getz, Integral Dental is committed to closing the gap between oral and systemic health through Next Generation Sequencing and Machine Learning technology. The cofounders bring extensive experience in biotech and health care, along with a dedication to preventative medicine. Integral is a resident company of Johnson & Johnson Innovation–JLABS, a premier life science incubator program located in Washington, D.C.